ProKidney Corp | Small-cap | Healthcare

TL;DR: Financial Overview - Revenue, Profits & Key Metrics

Latest Quarterly: Mar 2025

Income Metrics

Revenue 230.0K
Operating Income -41.4M -17,994.78%
Net Income -38.0M -16,500.87%
EPS (Diluted) $-0.13

Balance Sheet Metrics

Total Assets 406.1M
Total Liabilities 36.1M
Shareholders Equity 370.0M
Debt to Equity 0.10

Cash Flow Metrics

Operating Cash Flow -35.1M
Free Cash Flow -30.7M

Revenue & Profitability Trend

ProKidney Income Statement From 2020 to 2024

Metric20242023202220212020
Revenue i76.0K0000
Cost of Goods Sold i-----
Gross Profit i-----
Gross Margin % i0.0%0.0%0.0%0.0%0.0%
Operating Expenses
Research & Development i127.7M106.7M82.1M46.3M21.0M
Selling, General & Administrative i56.1M44.8M70.9M8.9M6.0M
Other Operating Expenses i-----
Total Operating Expenses i183.8M151.5M153.0M55.1M27.0M
Operating Income i-183.7M-151.5M-153.0M-55.1M-27.0M
Operating Margin % i-241,678.9%0.0%0.0%0.0%0.0%
Non-Operating Items
Interest Income i19.8M22.1M6.0M2.0K43.0K
Interest Expense i9.0K12.0K215.0K00
Other Non-Operating Income-----
Pre-tax Income i-163.9M-129.5M-147.2M-55.1M-27.0M
Income Tax i-598.0K6.0M896.0K38.0K-232.0K
Effective Tax Rate % i0.0%0.0%0.0%0.0%0.0%
Net Income i-163.3M-135.4M-148.1M-55.1M-26.7M
Net Margin % i-214,914.5%0.0%0.0%0.0%0.0%
Key Metrics
EBITDA i-158.5M-125.6M-144.0M-53.1M-26.0M
EPS (Basic) i$-0.62$-0.57$-0.23$-0.30$-0.14
EPS (Diluted) i$-0.62$-0.57$-0.23$-0.30$-0.14
Basic Shares Outstanding i979161936171422561540231186500000186500000
Diluted Shares Outstanding i979161936171422561540231186500000186500000

Income Statement Trend

ProKidney Balance Sheet From 2020 to 2024

Metric20242023202220212020
Assets
Current Assets
Cash & Equivalents i99.1M60.6M490.3M20.6M4.6M
Short-term Investments i259.2M302.3M0--
Accounts Receivable i-----
Inventory i-----
Other Current Assets80.0K9.0K1.4M25.0K52.0K
Total Current Assets i395.9M374.1M504.7M27.3M5.6M
Non-Current Assets
Property, Plant & Equipment i3.0M4.3M2.4M1.2M1.6M
Goodwill i-0213.0K428.0K642.0K
Intangible Assets i-----
Long-term Investments-----
Other Non-Current Assets-----
Total Non-Current Assets i45.2M46.4M13.3M13.0M11.1M
Total Assets i441.1M420.6M518.0M40.3M16.7M
Liabilities
Current Liabilities
Accounts Payable i3.6M5.1M3.0M2.8M781.0K
Short-term Debt i765.0K803.0K493.0K267.0K225.0K
Current Portion of Long-term Debt-----
Other Current Liabilities-----
Total Current Liabilities i36.2M25.0M10.9M12.3M5.5M
Non-Current Liabilities
Long-term Debt i2.5M3.6M1.9M1.1M1.3M
Deferred Tax Liabilities i-----
Other Non-Current Liabilities-----
Total Non-Current Liabilities i3.2M4.2M2.2M1.1M1.3M
Total Liabilities i39.4M29.2M13.1M13.4M6.8M
Equity
Common Stock i29.0K23.0K24.0K188.4M116.2M
Retained Earnings i-1.2B-1.1B-1.1B-161.5M-106.4M
Treasury Stock i-----
Other Equity-----
Total Shareholders Equity i401.6M391.3M504.9M26.9M9.9M
Key Metrics
Total Debt i3.2M4.4M2.4M1.3M1.6M
Working Capital i359.7M349.1M493.8M15.0M83.0K

Balance Sheet Composition

ProKidney Cash Flow Statement From 2020 to 2024

Metric20242023202220212020
Operating Activities
Net Income i-163.3M-135.4M-148.1M-55.1M-26.7M
Depreciation & Amortization i5.4M3.9M3.0M2.0M964.0K
Stock-Based Compensation i29.4M30.8M74.5M699.0K730.0K
Working Capital Changes i10.5M10.3M494.0K2.2M-126.0K
Operating Cash Flow i-118.2M-90.5M-70.1M-50.3M-25.2M
Investing Activities
Capital Expenditures i-29.5M-34.2M-1.8M-5.2M-5.5M
Acquisitions i-----
Investment Purchases i-324.0M-471.6M00-
Investment Sales i373.9M175.8M00-
Investing Cash Flow i20.4M-330.0M-1.7M-5.2M-5.5M
Financing Activities
Share Repurchases i0-9.5M00-
Dividends Paid i-----
Debt Issuance i-----
Debt Repayment i-54.0K-52.0K-35.0M-30.0K-11.0K
Financing Cash Flow i144.3M-9.6M513.5M71.5M20.0M
Free Cash Flow i-155.9M-124.3M-78.9M-55.5M-30.6M
Net Change in Cash i46.5M-430.0M441.6M16.0M-10.6M

Cash Flow Trend

ProKidney Key Financial Ratios

Valuation Ratios

P/E Ratio (TTM) -3.69
Forward P/E -4.65
Price to Book 0.88
Price to Sales 3,206.54
PEG Ratio 0.20

Profitability Ratios

Profit Margin 0.00%
Operating Margin -17,967.87%
Return on Equity -40.52%
Return on Assets -25.30%

Financial Health

Current Ratio 11.48
Debt to Equity 1.30
Beta 1.81

Per Share Data

EPS (TTM) $-0.56
Book Value per Share $-7.51
Revenue per Share $0.00

Peer Financial Comparison

CompanyMarket CapP/E RatioP/B RatioROEProfit MarginDebt/Equity
prok1.7B-3.690.88-40.52%0.00%1.30
Vertex 100.7B27.945.8622.77%31.86%8.89
Regeneron 62.9B14.952.0615.34%31.37%9.04
Adaptive 2.0B-12.0711.04-57.60%-59.07%121.39
Cg Oncology 2.0B-18.132.97-12.00%0.00%0.15
Vericel 1.8B259.145.962.59%2.85%32.74

Financial data is updated regularly. All figures are in the company's reporting currency.